Brought to you by 
TransForm licenses novel form of topiramate to J&J
05 Jan 2004
Executive Summary
TransForm Pharmaceuticals (employs automated platform technologies to optimize drug compounds and formulations) will assign its May 2003 patent covering a novel salt form of topiramate to Johnson & Johnson Pharmaceutical R&D in exchange for up-front money, milestones, and royalties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TransForm licenses novel form of topiramate to J&J
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice